CNS delivery of therapeutic agents
US12409210B2 · kind B2 · utility
0Cited by
24References
5Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Aug 16, 2022 |
| Grant date | Sep 9, 2025 |
| Priority date | — |
| Expiry date | Aug 16, 2042 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12Y310/01001
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides an effective and less invasive approach for direct delivery of therapeutic agents to the central nervous system (CNS). In some embodiments, the present invention provides methods including a step of administering intrathecally to a subject suffering from or susceptible to a lysosomal storage disease associated with reduced level or activity of a lysosomal enzyme, a composition comprising a replacement enzyme for the lysosomal enzyme.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.